SDF-1/CXCR4在肿瘤相关成纤维细胞中的作用

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (9): 1256-1260.

SDF-1/CXCR4在肿瘤相关成纤维细胞中的作用

于彪, 刘晴, 吴晓明^*

昆明理工大学医学院, 云南昆明 650500

收稿日期:2019-11-04 修回日期:2020-03-28 出版日期:2020-09-05 发布日期:2020-09-04
通讯作者: ^*xiao_tracy@163.com
基金资助:
国家自然科学基金(81960529)

Role of SDF-1/CXCR4 in cancer-associated fibroblasts

YU Biao, LIU Qing, WU Xiao-ming^*

Medical Faculty, Kunming University of Science and Technology, Kunming 650500, China

Received:2019-11-04 Revised:2020-03-28 Online:2020-09-05 Published:2020-09-04
Contact: ^*xiao_tracy@163.com

摘要/Abstract

摘要： 肿瘤相关成纤维细胞(CAFs)是肿瘤微环境的重要组成成分,分泌多种因子在恶性肿瘤发生、发展过程中起重要作用。CAFs来源的基质细胞衍生因子-1(SDF-1)通过其特异性受体CXCR4以自分泌或旁分泌方式调控包括CAFs的激活和维持、肿瘤的增殖、侵袭和转移,血管生成、肿瘤耐药等在内的肿瘤生物学行为。因此,靶向SDF1/CXCR4 能为抑制肿瘤进展、临床肿瘤治疗提供新策略。

Abstract: Cancer-associated fibroblasts (CAFs), important component of tumor microenvironment, secrete a variety of factors that play an important role in the occurrence and development of malignant tumors. Stromal cell derived factor-1(SDF-1) secreted by CAFs and its specific receptor CXCR4 can promote the activation and maintenance of CAFs, regulate tumor biological behaviors including tumor proliferation and survival, tumor angiogenesis, invasion and metastasis, and drug resistance in autocrine or paracrine manner. Therefore, research targeting at SDF-1/CXCR4 may provide a new strategy for inhibiting tumor progression and clinical treatment.

Key words: cancer-associated fibroblasts(CAFs), stromal cell derived factor-1(SDF-1), CXCR4

中图分类号:

R730

于彪, 刘晴, 吴晓明. SDF-1/CXCR4在肿瘤相关成纤维细胞中的作用[J]. 基础医学与临床, 2020, 40(9): 1256-1260.

YU Biao, LIU Qing, WU Xiao-ming. Role of SDF-1/CXCR4 in cancer-associated fibroblasts[J]. Basic & Clinical Medicine, 2020, 40(9): 1256-1260.

参考文献

[1] Nurmik M, Ullmann P, Rodriguez F, et al. In search of definitions: Cancer-associated fibroblasts and their markers[J].Int J Cancer, 2019, 146: 895-905.
[2] Daniel SK, Seo YD, and Pillarisetty VG. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resist-ance in gastrointestinal malignancies[J].Semin Cancer Biol, 2019.doi:10.1016/j.semcancer.2019.12.007.
[3] Freitas C, Desnoyer A, Meuris F, et al. The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers[J].Cytokine Growth Factor Rev, 2014, 25: 307-316.
[4] Rajagopal S, Kim J, Ahn S, et al. Beta-arrestin-but not G protein-mediated signaling by the “decoy” receptor CXCR7[J].Proc Natl Acad Sci U S A, 2010, 107: 628-632.
[5] Daniel SK, Seo YD, and Pillarisetty VG. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resis-tance in gastrointestinal malignancies[J].Semin Cancer Biol, 2019. doi:10.1016/j.semcancer.2019.12.007.
[6] Ando N, Furuichi Y, Kasai S, et al. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements[J].Leuk Res, 2018, 75: 36-44.
[7] Zhao D, Qin W, Zhao C, et al. CXCR7, a prognostic biomarker in cervical squamous cell carcinoma, may be a screening index for treatment options at stages IB1 and IIA1[J].Cancer Manag Res, 2019, 11: 10287-10296.
[8] Xin Q, Zhang N, Yu HB, et al. CXCR7/CXCL12 axis is involved in lymph node and liver metastasis of gastric carcinoma[J].World J Gastroenterol, 2017, 23: 3053-3065.
[9] Huang TX, Guan XY, and Fu L. Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells[J].Am J Cancer Res, 2019, 9: 1889-1904.
[10] Wei L, Ye H, Li G, et al. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer[J].Cell Death Dis, 2018, 9: 1065.doi:10.1038/S41419-018-1104-x.
[11] Choi, HS, Lee K, Kim MK, et al. DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis[J].Oncotarget, 2016, 7: 21775-21785.
[12] Ribatti D. Tumor refractoriness to anti-VEGF therapy[J].Oncotarget, 2016, 7: 46668-46677.
[13] Marques P, Barry S, Carlsen E, et al. Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness[J].Endocr Relat Cancer, 2019, 26:853-865.
[14] Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion[J].Cell, 2005, 121: 335-348.
[15] Li X, Bu W, Meng L, et al. CXCL12/CXCR4 pathway orchestrates CSC-like properties by CAF recruited tumor associated macrophage in OSCC[J].Exp Cell Res, 2019, 378: 131-138.
[16] Kinoshita H, Yashiro M, Fukuoka T, et al. Diffuse-type gastric cancer cells switch their driver pathways from FGFR2 signaling to SDF1/CXCR4 axis in hypoxic tumor microenvironments[J].Carcinogenesis, 2015, 36: 1511-1520.
[17] Ham SL, Thakuri PS, Plaster M, et al. Three-dimen-sional tumor model mimics stromal-breast cancer cells signaling[J].Oncotarget, 2018, 9: 249-267.
[18] Gok Yavuz B, Gunaydin G, Gedik ME, et al. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1⁺ TAMs[J].Sci Rep, 2019, 9: 3172.doi:10.1038/S41598-019-39553-z.
[19] Teng F, Tian WY, Wang YM, et al. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis[J].J Hematol Oncol, 2016, 9: 8.doi:10.1186/S13045-015-0231-4.
[20] Song T, Dou C, Jia Y, et al. TIMP-1 activated carcinoma-associated fibroblasts inhibit tumor apoptosis by activating SDF1/CXCR4 signaling in hepatocellular carcinoma[J].Oncotarget, 2015, 6: 12061-12079.
[21] 邹芳,张志华,张玉妥,等.肿瘤相关成纤维细胞通过分泌基质细胞衍生因子1调节肺癌A549细胞的耐药性[J].中华肿瘤杂志,2017, 39: 339-343.
[22] Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer[J].Cancer Cell, 2018, 33:463-479.
[23] Nakamura T, Shinriki S, Jono H, et al. Intrinsic TGF-beta2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells[J].Oncotarget, 2015, 6: 1008-1019.
[24] Chang PH, Hwang-Verslues WW, Chang YC, et al. Activation of Robo1 signaling of breast cancer cells by Slit2 from stromal fibroblast restrains tumorigenesis via blocking PI3K/Akt/β-catenin pathway[J].Cancer Res, 2012, 72: 4652-4661.